Product & Technology - DABRA is an excimer laser system with disposable catheters for treating peripheral artery disease (PAD) by crossing total chronic occlusions (CTOs) and ablating a channel[7] - DABRA utilizes photoablation to disintegrate plaque in the artery and is designed to track the patient's true lumen[8,19] - PHAROS, using the same laser platform as DABRA, has US FDA 510(k) clearance and Europe CE Mark for treating psoriasis, vitiligo, atopic dermatitis, and leukoderma[8] Clinical & Market - In a pivotal study, DABRA demonstrated 94% effectiveness in successful crossing of target lesions based on angiographic analysis[26] - The company targets a $1.1 billion global annual total addressable market (TAM) with over 17 million PAD sufferers in the US[9,28] - Only 20% to 30% of peripheral artery disease patients are actively being treated[12,28] Financials - For the six months ended June 30, 2020, total net revenue was $2.274 million, including $191 thousand from vascular and $2.083 million from dermatology[53] - For the year ended December 31, 2019, total net revenue was $7.199 million, including $1.275 million from vascular and $5.924 million from dermatology[53] - As of June 30, 2020, the company had $29.380 million in cash and cash equivalents and short-term investments[55]
Ra Medical Systems (RMED) Investor Presentation - Slideshow